AGP Executive Report
Last update: 5 hours agoBiotech M&A: Eli Lilly agreed to acquire Merida Biosciences for up to $2.88B, a targeted bet on autoimmune/allergy therapies that could reshape Lilly’s pipeline and investor expectations. Regulatory Scrutiny: The SEC is pressing investment firms to prove their SPVs actually hold shares in private startups, raising compliance pressure across private-investment access products. Shareholder Rights / Class Actions: A wave of investor-rights deadlines continues, including Rosen Law notices tied to Bloom Energy (Sept. 28), Wise Group (Sept. 29), and multiple other public companies—investors are being urged to seek lead-plaintiff roles. State Economic Policy: New Mexico opened Capital Leverage and Targeted Federal Match grants that require companies to bring outside investment, aiming to multiply tech funding. Corporate Governance: A Reuters report says global opposition to executive pay eased, even as voting becomes more fragmented. Market Data: The U.S. Treasury released preliminary TIC figures showing year-end 2025 foreign holdings of U.S. securities at about $19.3T. Investor Events: Investor Summit Group made Q3 virtual conference presentations available on demand, while IBTM Ignite returns in Barcelona to connect investors with emerging event-industry businesses.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
